At the news
? MIXEDIMPACT 6/10 8-K filed Feb 25, 2026 at 07:05 ET
Alkermes reported 2025 total revenues of $1.48 billion and diluted GAAP EPS of $1.43, with a 9% year-over-year increase in proprietary product sales. The company expects a GAAP net loss in 2026 due to acquisition-related costs from the Avadel deal, despite projecting revenue growth to $1.73-$1.84 billion. The acquisition of Avadel strengthens its sleep medicine portfolio with LUMRYZ and supports the development of alixorexton.
- 2025 total revenue was $1.48 billion, down from $1.56 billion in 2024
- 2025 GAAP net income was $242 million, down from $367 million in 2024
- 2026 guidance includes a projected GAAP net loss of $115-$135 million
- 2026 revenue guidance is $1.73-$1.84 billion, representing 17-24% growth
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access